European Medicines Agency’s Post

🌟 Important Update on Medicine Shortages 🌟 🚨 The EMA and HMA are addressing shortages of essential diabetes and weight management drugs like Ozempic, Saxenda, Trulicity, and Victoza. 🚨 🌍💊 Importance of GLP-1 Receptor Agonists: These medicines are crucial for managing diabetes and weight in people with obesity or related health issues. 📈 Why the Shortages? Since 2022, high demand and manufacturing issues have led to shortages, worsened by misuse for cosmetic weight loss and the risk of fake products. 🚫💊 🔍 Here's what they're doing to help: ➡️ Collaborating: Bringing together industry, regulators, healthcare professionals, and the public. ➡️ Controlling Distribution: Working with manufacturers to ensure fair distribution. ➡️ Prioritising Patients: Making sure those who need these medicines the most get them. ➡️ Boosting Production: Increasing manufacturing capacity. ➡️ Educating: Raising awareness about the proper use of these drugs. A big workshop is scheduled for July 1, 2024, to discuss more solutions. ✅ A big workshop is scheduled for July 1, 2024, to discuss more solutions. 🤝 👥 For the public: ➡️ Use these medicines only under medical supervision. ⚠️ ➡️ Avoid buying from unverified online sources. ❌ ➡️ Talk to your doctor if your medicine is unavailable. 💬 🔗 More info: EMA Official Site hashtag #Healthcare hashtag #Pharmaceuticals hashtag #GLP1 hashtag #DiabetesCare hashtag #WeightManagement hashtag #PublicHealth hashtag #MedicineShortages hashtag #PatientCare hashtag #DrugSafety hashtag #MedicalUpdates hashtag #RegulatoryActions hashtag #HealthAwareness hashtag #DiabetesManagement hashtag #WeightLoss hashtag #ObesityTreatment @EMA_News @HMA_Health @DiabetesUK @DiabetesAssoc @HealthEU @ObesitySociety @PharmaNews @Healthline @WHO @UNHealth

Healthcare is a fascinating area of balancing needs and wants.

Discover the science behind one of the most exciting and controversial advancements in weight management: GLP-1 receptor agonist medications. In this video, we delve into how these medications aid in weight loss, their mechanism of action, and the potential benefits they offer. We also explore the possible risks and side effects to give you a comprehensive understanding of these treatments.

Besides Benzodiazepines and Barbiturates, other Hypnotic agents include the following: 1. Zolpidem 2. Zaleplon 3. Eszopiclone 4. Melatonin Receptor Agonist 5. Antihistamines 6. Antidepressants 7. Suvorexant

WHAT ARE GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR AGONISTS? https://lnkd.in/eCDBgtSG

#ArticlesInPress: GLP-1 receptor agonists and vascular protection Brady Park et al. https://ow.ly/XV6I50R499w #atherosclerosis #endothelialdysfunction #oxidative stress

In response to those who believe that there may be benefit from combining the CGM system with GLP-1 infusion to overcome the problem of rapid degradation of GLP-1, it is noted that analogues (GLP receptor agonists) have been developed -1) with a structure more or less similar to GLP-1 which resists the degradation action exerted by DPP-4.

🌟Spotlight Cover🌟 GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage https://ow.ly/3BS250RGWuM #Inflammation #Atherosclerosis #GLP1ReceptorAgonists

(b) Antagonists Ligands that prevent an agonist from binding to a receptor and thus prevent its effects are called antagonists. Antagonists do not themselves have any pharmacological actions mediated by receptors. For example, propranolol, a β-adrenoceptor antagonist, binds to β-adrenoceptors in the heart and prevents catecholamine-induced tachycardia (for example in response to exercise). However, in the absence of an agonist propranolol has no effect via adrenoceptors.

Q. Indicate D2 receptor agonist with antiparkinsonian activity: a) Sinemet b) Levodopa c) Bromocriptine d) Selegiline